Lyell Immunopharma annual operating margin
2019
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Operating Margin Growth & History (LYEL)
Lyell Immunopharma's operating margin was −748,344.44% for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −748,344.44% | −160221.49 pp |
| 2024 | 2024-12-31 | −588,122.95% | −398116.80 pp |
| 2023 | 2023-12-31 | −190,006.15% | −189785.26 pp |
| 2022 | 2022-12-31 | −220.89% | +1795.78 pp |
| 2021 | 2021-12-31 | −2,016.68% | +715.88 pp |
| 2020 | 2020-12-31 | −2,732.56% | +12806.11 pp |
| 2019 | 2019-12-31 | −15,538.66% | — |
Lyell Immunopharma quarterly operating margin
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −1,183,425.00% | −594175.00 pp |
| Q1 2026 | 2026-03-31 | −2,213,050.00% | −1393521.43 pp |
| Q4 2025 | 2025-12-31 | −2,127,400.00% | −298790.91 pp |
| Q3 2025 | 2025-09-30 | −248,353.33% | −99809.22 pp |
| Q2 2025 | 2025-06-30 | −589,250.00% | −192880.77 pp |
| Q1 2025 | 2025-03-31 | −819,528.57% | +1032971.43 pp |
| Q4 2024 | 2024-12-31 | −1,828,609.09% | −1370855.24 pp |
| Q3 2024 | 2024-09-30 | −148,544.12% | +87611.88 pp |
| Q2 2024 | 2024-06-30 | −396,369.23% | −152276.64 pp |
| Q1 2024 | 2024-03-31 | −1,852,500.00% | −1756260.00 pp |
| Q4 2023 | 2023-12-31 | −457,753.85% | −457723.29 pp |
| Q3 2023 | 2023-09-30 | −236,156.00% | +1978410.67 pp |
| Q2 2023 | 2023-06-30 | −244,092.59% | −243988.34 pp |
| Q1 2023 | 2023-03-31 | −96,240.00% | −83839.28 pp |
| Q4 2022 | 2022-12-31 | −30.55% | +1654.00 pp |
| Q3 2022 | 2022-09-30 | −2,214,566.67% | −2212782.24 pp |
| Q2 2022 | 2022-06-30 | −104.25% | +2281.86 pp |
| Q1 2022 | 2022-03-31 | −12,400.72% | −10136.10 pp |
| Q4 2021 | 2021-12-31 | −1,684.55% | +1758.72 pp |
| Q3 2021 | 2021-09-30 | −1,784.43% | +1505.05 pp |
| Q2 2021 | 2021-06-30 | −2,386.11% | — |
| Q1 2021 | 2021-03-31 | −2,264.62% | — |
| Q3 2020 | 2020-09-30 | −3,443.27% | — |
| Q2 2020 | 2020-06-30 | −3,289.48% | — |
Lyell Immunopharma operating margin trends
Over the last five reported fiscal years, Lyell Immunopharma's operating margin decreased from −2,732.56% to −748,344.44%, a change of −745611.89 percentage points. The latest reported quarter, Q2 2026, shows −1,183,425.00%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma filings at SEC.gov ↗